Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.

Gastroenterology - 1 Jun 2006

Gallmeier Eike, Calhoun Eric S, Rago Carlo, Brody Jonathan R, Cunningham Steven C, Hucl Tomas, Gorospe Myriam, Kohli Manu, Lengauer Christoph, Kern Scott E

Abstract excerpt

BACKGROUND & AIMS: How specifically to treat pancreatic and other cancers harboring Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies have been hampered by the lack of well-controlled human cancer models. METHODS: We endogenously disrupted FANCC and FANCG in a human adenocarcinoma cell line and determined the impact of these genes on drug sensitivity, irradiation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blotting, Western

Share to Chromosome Breakage

Share to Immunoprecipitation

Share to In Situ Hybridization

Share to Karyotyping

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 16762635
DOI: 10.1053/j.gastro.2006.03.016

Genes

FANCG
FANCC
FANCD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.PMID 16762635Read ↗

Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9.Semantic proximity Read ↗

Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.Semantic proximity Read ↗

Fanconi anemia-isogenic head and neck cancer cell line pairs - a basic and translational science resourceSemantic proximity Read ↗

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.Semantic proximity Read ↗

A C57BL/6J Fancg-KO Mouse Model Generated by CRISPR/Cas9 Partially Captures the Human Phenotype.Semantic proximity Read ↗

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.Semantic proximity Read ↗

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapySemantic proximity Read ↗

Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and TherapySemantic proximity Read ↗

Fanconi anemia‐isogenic head and neck cancer cell line pairs: A basic and translational science resourceSemantic proximity Read ↗

Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia.Semantic proximity Read ↗

Drosophila homologs of FANCD2 and FANCL function in DNA repair.Semantic proximity Read ↗

The Fanconi anaemia genome stability and tumour suppressor network.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.